Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 4/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | FER | P16591 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19492450 | 0.73 | TSHR (0.47) | IDO1TNKS2KMT2ATSHRLMNA | |
| SCHEMBL31739367 | 0.73 | TSHR (0.47) | IDO1TNKS2KMT2ATSHRLMNA | |
| SCHEMBL22268104 | 0.67 | HTR2A (0.35) | IDO1TNKS2KMT2ATSHRMEN1 | |
| SCHEMBL22130542 | 0.65 | IDO1 (0.36) | IDO1NOS2TNKS2KMT2ALMNA | |
| SCHEMBL13949315 | 0.64 | MAPT (0.43) | IDO1NOS2TNKS2KMT2ATSHR | |
| SCHEMBL11100808 | 0.63 | HRH1 (0.39) | IDO1KMT2ALMNAGAAKDM4E | |
| SCHEMBL22478921 | 0.62 | BRD3 (0.40) | KMT2ATSHRLMNAMEN1GAA | |
| SCHEMBL23615537 | 0.62 | CREBBP (0.59) | IDO1KMT2ATSHRMEN1GAA | |
| SCHEMBL22522329 | 0.62 | IDO1 (0.38) | IDO1NOS2TNKS2KMT2ATSHR | |
| SCHEMBL19465426 | 0.62 | TNKS2 (0.55) | TNKS2KMT2ATSHRMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403789-B2 | Benzofuran-containing amino acid inhibitors of cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-8952056-B2 | Methods for inhibiting drug degradation | SEQUOIA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8703700-B2 | Bimacrocylic HCV NS3 protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8673970-B2 | HIV protease inhibitor and cytochrome p450 inhibitor combinations | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2432318-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | Sequoia Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2422780-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110124578-A1 | AMINO ACID INHIBITORS OF CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2005087728-A9 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1750696-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1732891-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050209301-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005087728-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124578-A1 | AMINO ACID INHIBITORS OF CYTOCHROME P450 | CYP3A43, CYP7A1, CYP3A5 | IDO1 275/4885NOS2 394/4885TNKS2 3678/4885 |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | IDO1 1811/4885NOS2 4298/4885TNKS2 3985/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | IDO1 1811/4885NOS2 4298/4885TNKS2 3985/4885 |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | IDO1 1960/4885NOS2 3719/4885TNKS2 2335/4885 |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | IDO1 767/4885NOS2 448/4885TNKS2 1252/4885 |
| US-20050209301-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | IDO1 1811/4885NOS2 4298/4885TNKS2 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.